Condition
Extensive Stage Lung Small Cell Cancer
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
P 2 (5)
Trial Status
Recruiting3
Not Yet Recruiting2
Clinical Trials (5)
Showing 5 of 5 trials
NCT07057791Phase 2RecruitingPrimary
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer
NCT07203053Phase 2RecruitingPrimary
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
NCT07172412Phase 2Not Yet RecruitingPrimary
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
NCT07061535Phase 2Not Yet Recruiting
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT06350162Phase 2RecruitingPrimary
Testing the Addition of Radiation Therapy to the Immune Therapy Treatment for ES-SCLC
Showing all 5 trials